The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent

समान संसाधन

• Combination therapies augment the anti-tumor activity of agonist CD27 mAb in human CD27 transgenic mouse models
  द्वारा: He, Li-Zhen, और अन्य
  प्रकाशित: (2013)
• CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy
  द्वारा: Wasiuk, Anna, और अन्य
  प्रकाशित: (2017)
• Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
  द्वारा: Ramakrishna, Venky, और अन्य
  प्रकाशित: (2015)
• Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine
  द्वारा: He, Li-Zhen, और अन्य
  प्रकाशित: (2015)
• Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
  द्वारा: Ansell, Stephen M., और अन्य
  प्रकाशित: (2020)